Perbandingan kadar nerve growth factor serum antara painful dan nonpainful diabetic neuropathy
https://doi.org/10.22146/bns.v18i1.55066 Dwi Ananda Puspitasari(1*), Ahmad Asmedi(2), Abdul Gofir(3)
(1)
(2) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta
(3) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author
Abstract
Kontroversi tentang peran nerve growth factor (NGF) terhadap patogenesis nyeri membatasi pengembangan terapi neuropati diabetika berbasis NGF. Beberapa penelitian menyebutkan bahwa NGF menimbulkan efek antinosiseptik, sementara yang lainnya menyebutkan NGF menimbulkan efek pronosiseptik. Diperlukan suatu penelitian yang dapat membantu memahami peran NGF terhadap patogenesis nyeri neuropati diabetika (painful diabetic neuropathy). Penelitian ini bertujuan untuk membandingan kadar NGF serum antara painful dan non painful diabetic neuropathy.
Penelitian ini menggunakan rancangan cross sectional, dengan subjek penelitian pasien DM tipe 2 yang telah tegak diagnosis neuropati diabetika berdasarkan klinis dan pemeriksaan elektroneuromiografi (ENMG) yang kontrol ke Poliklinik Saraf RSUP Dr. Sardjito. Painful diabetic neuropathy ditentukan berdasarkan skor ID pain. Kadar NGF serum diperiksa dengan kit reagen NGF manusia ELISA produk Abnova. Analisis statistik dengan uji t digunakan untuk menilai signifikansi dari perbandingan yang muncul. Nilai p <0,05 dianggap sebagai signifikan.
Tiga puluh enam pasien neuropati diabetika berperan dalam penelitian ini, terdiri dari 21 kasus painful diabetic neuropathy dan 15 kasus non painful diabetic neuropathy. Hasil uji statistik menunjukkan tidak terdapat perbedaan rerata kadar NGF serum antara painful dan non painful diabetic neuropathy. Meskipun demikian, terdapat korelasi negatif antara kadar NGF serum dengan skor ID pain yang berarti semakin rendah kadar NGF serum maka semakin tinggi skor ID pain (p <0,05 dan r = -0,414).
Tidak terdapat perbedaan kadar NGF serum yang signifikan antara painful dan nonpainful diabetic neuropathy.
Keywords
Full Text:
PDFReferences
1.Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660–674.
2.Bosi E, Conti M, Vermigli C, Cazzetta G, Peretti E, Cordoni C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005;48:817–823.
3.Vinik A I, Pittenger G, Stansberry K, Park TS, Erbas, T. Neurotrophic factors. In: Gries FA, Low PA, Cameron NE, Ziegler D. Textbook of Diabetic Neuropathy. Stuttgart: Georg Thieme Verlag; 2003;p.129–169.
4.Khan N, Smith M. Neurotrophins and Neuropathic Pain: Role in Pathobiology. Molecules. 2015;20:10657-10688.
5.Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig. 2014;5(6):714-721.
6.Faradji V, Sotelo J. Low serum levels on nerve growth factor in diabetic neuropathy. Acta Neurol Scand. 1990;81(5):402-406.
7.Kim HC, Cho YJ, Ahn CW, Park JC, Kim JS, Nam YS, et al. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med. 2009;26(12):1228-1234.
8.Lang UE, Gallinat J, Hopfe H, Bajbouj M, Hellweg R. Nerve growth factor serum concentrations in healthy human volunteers: physiological variance and stability. Neurosci Lett. 2003;344(1):13-16.
9.Prasetyo GA, Setyaningsih I, Dahlan P. Lama menderita diabetes mellitus tipe 2 sebagai faktor risiko nyeri neuropati diabetik. (Tesis). Yogyakarta: Pascasarjana Universitas Gadjah Mada; 2010.
10.Maryanto D, Meliala L, Wibowo S. Gula darah tidak terkontrol sebagai faktor risiko nyeri neuropati diabetika pada penderita diabetes mellitus tipe 2. (Tesis).Yogyakarta: Pascasarjana Universitas Gadjah Mada; 2009.
11.Jambart S, Ammache Z, Haddad F.Prevalence of Painful Diabetic Peripheral Neuropathy among Patients with Diabetes Mellitus in the Middle East Region. Journal of International Medical Research. 2011;39:366-378.
12.Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, et al.Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35(3):206-213.
13.Tolle T,Xu X, Sadosky AB. Painful Diabetic Neuropathy: a cross sectional survey of health state impairment and treatment pattern. Journal of Diabetes and Its Complications. 2006;20:26-33.
14.Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: Where are we now and where to go? Journal of Diabetes Investigation. 2010;2(1):18-27.
15.Chalkadov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in vascular disease? Progress in Brain Research. 2004;146:279-289.
16.Portenoy R. Development and testing for a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006;22:1555-1565.
DOI: https://doi.org/10.22146/bns.v18i1.55066
Article Metrics
Abstract views : 778
| 
views : 468
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Berkala NeuroSains
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.